Merck & Co. stock edges higher as analysts hold to cautious targets

Published on 09/16/2026 at 14:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck & Co. stock traded around USD 143 on September 15, 2026, leaving it below analyst fair value estimates and recent price targets. Current oncology and technology initiatives add potential, while risks around valuation and competition remain in focus.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c — Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co., Inc. stock (ISIN US58933Y1055) recently traded close to USD 143 on the New York Stock Exchange as of around mid-September 2026, keeping the shares below several fair value estimates and price targets that cluster near USD 150 per share and above.

Analyst views and valuation check

According to Morningstar on September 16, 2026, one widely followed narrative for Merck values the stock at about USD 150.42 per share, compared with a recent closing price of roughly USD 143.79, implying an undervaluation of around 4 percent based on that framework.

As Yahoo Finance reported on September 15, 2026, Merck’s pipeline value is estimated at about USD 70 billion, and the stock has pulled back roughly 7 percent from its one-month high, which keeps investor attention on whether the current premium valuation is justified by future growth.

Ratings signal cautious optimism

In the analyst community, views on Merck remain mixed but broadly constructive. According to The Globe and Mail on September 16, 2026, RBC Capital analyst Trung Huynh maintains a Hold rating on Merck & Company with a price target of USD 150.00 per share, which sits several dollars above the recent trading level near USD 143 and thus embeds moderate upside but not an aggressive bull stance.

The same overview notes that Barclays analyst Emily Field also holds Merck at a Hold rating, while DBS keeps a Buy rating on the shares, reflecting how the consensus leans toward Merck as a solid large-cap pharmaceutical name rather than a high-conviction outperformer at current prices.

Pipeline and strategic moves underpin the story

Growth expectations for Merck depend heavily on its oncology portfolio and broader pipeline. As Simply Wall St highlighted on September 16, 2026, Merck has expanded the reach of clinical trials for Keytruda, its leading cancer immunotherapy, which supports expectations for continued revenue growth in oncology and helps underpin the fair value estimate around USD 150.42 per share.

At the same time, Yahoo Finance reported in early September 2026 that Merck entered an oncology collaboration and rolled out a technology pilot linking its M-Trust physical authentication platform with blockchain-based digital product passports, illustrating how the company seeks to leverage technology to strengthen supply chain traceability and regulatory compliance beyond pure drug development.

Market performance and recent price action

The shares have shown a solid medium-term performance. According to Simply Wall St on September 16, 2026, Merck shares trade at about USD 143.79 with a 30-day share price return of roughly 5.85 percent and a 90-day return of around 24.56 percent, indicating that the stock has significantly outperformed many defensive healthcare peers over the past quarter.

That performance comes despite the recent 7 percent pullback from the one-month high mentioned in the Yahoo Finance valuation piece, which suggests that some profit-taking has occurred but that the broader uptrend since earlier in the year remains intact as long as the price stays comfortably above prior lows and near the range implied by the USD 150-level price targets.

Stock level and investor takeaway

With Merck & Co. stock trading around USD 143 on the New York Stock Exchange as of about mid-September 2026, the shares sit several dollars below the USD 150.00 price target maintained by RBC Capital and just under the approximate USD 150.42 fair value figure cited by valuation-focused analysis, a gap that investors will watch as new oncology data and technology initiatives emerge.